Showing 4111-4120 of 10499 results for "".
- Foamix Announces Additional Phase 3 Trial for FMX101 in Moderate to Severe Acnehttps://practicaldermatology.com/news/foamix-announces-additional-phase-3-trial-for-fmx101-in-moderate-to-severe-acne/2458203/Foamix Pharmaceuticals is launching an additional Phase 3 trial for FMX101 in moderate to severe acne, a topical minocycline treatment. If the results are positive, this new Phase 3 trial is expected to form the basis for a New Drug Application (NDA) which the company plans to submit in t
- ACLARIS files NDA For Novel Seborrheic Keratosis Treatmenthttps://practicaldermatology.com/news/aclaris-files-nda-for-novel-seborrheic-keratosis-treatment/2458272/Aclaris Therapeutics, Inc. submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for A-101 40% topical solution (A-101) as a treatment for seborrheic keratosis (SK). If approved, A-101 would be the first FDA-approved t
- Study: Anxiety, Depression May Travel with Hyperhidrosishttps://practicaldermatology.com/news/anxiety-depression-may-travel-with-hyperhidrosis/2458367/Individuals with hyperhidrosis are more likely to be anxious or depressed than their colleagues who don’t sweat excessively, new research suggests. Specifically, the prevalence of anxiety and depression was 21.3 percent and 27.2 percent in patients with hyperhidrosis, resp
- Study: 98% of Head Lice in at Least 42 States Now Resistant to Common OTC Treatmentshttps://practicaldermatology.com/news/98-of-head-lice-in-at-least-42-states-now-resistant-to-common-otc-treatments/2458480/Fully 98 percent of head lice in at least 42 states are resistant to various over-the-counter pyrethrins and pyrethroids including permethrin, which is the active ingredient in popular treatment formulations for pediculosis (Nix® (permethrin 1%), according to a study in t
- Indoor Tanning Rates Among Minors in NJ Stays Same Despite 2013 Banhttps://practicaldermatology.com/news/indoor-tanning-rates-among-minors-in-nj-stays-same-despite-2013-ban/2458494/Indoor tanning rates among children under age 17 in New Jersey didn’t budge after a ban enacted in 2013, and rates increased among male high school students in the Garden State from 2012 to 2014, according to a study in the Journal
- A Novel Dual-Wavelength, Nd:YAG, Picosecond-domain Laser Safely and Effectively Removes Multicolor Tattooshttps://practicaldermatology.com/news/a-novel-dual-wavelength-ndyag-picosecond-domain-laser-safely-and-effectively-removes-multicolor-tattoos/2458848/Research conducted by Eric F. Bernstein MD, MSc; Kevin T. Schomacker PhD; Lisa D. Basilavecchio RN; Jessica M. Plugis; and Jayant D. Bhawalkar PhD, published in the September 2015 issue of Lasers in Surgery and Medicine (LSM), evaluated 21 tattooed subjects between the ages of 19-55 who
- TetraLogic Pharmaceuticals Presents SHAPE at Annual Society of Investigative Dermatology Meetinghttps://practicaldermatology.com/news/20140506-tetralogic_pharmaceuticals_presents_shape_at_annual_society_of_investigative_dermatology_meeting/2459246/TetraLogic Pharmaceuticals Corporation presented results from the Phase I randomized, placebo-controlled clinical study of SHAPE (formerly SHP-141) in Stage IA -IIA Cutaneous T Cell Lymphoma (CTCL) at the annual Society of Investigative Dermatology Meeting, which was held in Albuquerque, New Mexi
- TetraLogic Acquires Shape Pharmaceuticals, Inc.https://practicaldermatology.com/news/20140407-tetralogic_acquires_shape_pharmaceuticals_inc/2459275/TetraLogic Pharmaceuticals Corporation has entered an agreement to acquire Shape Pharmaceuticals, a biotechnology company. Shape Pharmaceuticals is developing SHAPE, which is a tissue-targeted HDAC inhibitor in a topical gel formulation to treat stage IA-IIA Cutaneous T-Cell Lymphoma.
- Indoor Tanning Among High Schoolers Linked to Other Risky Behaviorhttps://practicaldermatology.com/news/20140227-indoor_tanning_among_high_schoolers_linked_to_other_risky_behavior/2459329/A national survey of high school students found that indoor tanning is a common practice, particularly among female, older and non-Hispanic white students, and is associated with several other risky health-related behaviors, according to a study by Gery P. Guy Jr., PhD, MPH of t
- Speedier Drug Approvals Not Tied to Increased Warnings or Health Riskshttps://practicaldermatology.com/news/20130815-speedier_drug_approvals_not_tied_to_increased_warnings_or_health_risks/2459478/Faster drug approvals in the US and Canada are not linked to increases in the number of serious drug safety warnings issued by regulators, nor to actual evidence of health risks, according to new research. Investigators compared data about the number of drug safety warnings issued by regulators in t